Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-04: ctDNA-Guided Adjuvant Chemotherapy in High-Risk Colorectal Cancer
NCT07562490Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07562490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562490.